ELAB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ELAB ▼ -62.99% at T+20d

NEUTRAL call ✗ call lost -62.99% · α vs SPY -70.72% · entry $5.08 → $1.88

Next anchor: T+60d in 23d

Last close $1.47 (close Jun 12) · -71.06% from $5.08 entry

Entry anchored
Apr 13, 07:29 AM ET
via Databento tick

T+1d

-13.78%

call -13.78% · α -14.99%

$4.38

settled 2mo ago

T+5d

-34.65%

call -34.65% · α -37.94%

$3.32

settled 8w ago

T+20d

-62.99%

call -62.99% · α -70.72%

$1.88

settled 5w ago

T+60d

—

call — · α —

—

in 23d

Price Chart

Loading chart...

Executive Summary

PMGC Holdings subsidiary NorthStrive Biosciences announced the transfer of the EL-32 Working Cell Bank to a U.S. third-party fermentation facility, initiating a manufacturing optimization program to improve yield and scalability for future clinical and commercial development. The move supports parallel development of EL-32 in human therapeutics and non-human animal health applications via a licensing partnership with Modulant Biosciences.

Actionable Insight

Monitor progress in process optimization and future IND-enabling milestones, which could validate scalability and de-risk the platform. The collaboration with Modulant may provide shared manufacturing insights, but no near-term revenue or earnings catalyst is evident.

Key Facts

NorthStrive Biosciences transferred the EL-32 Working Cell Bank to a U.S.-based third-party fermentation facility.
The transfer initiates a manufacturing optimization program aimed at increasing production yield and scalability.
Modulant Biosciences, licensee for non-human animal health applications, is leading process development.
NorthStrive retains rights to human therapeutic applications of EL-32.
EL-32 is an engineered probiotic targeting myostatin and activin-A pathways for muscle preservation in patients on GLP-1 weight loss therapies.

Financial Impact

No immediate financial impact disclosed; long-term potential tied to future clinical/commercial success.

revenueR&D expensedilution

Risk Factors

Manufacturing optimization may fail to achieve desired yield or scalability.
Forward-looking statements carry inherent uncertainty; actual results may differ materially.
Company has limited market cap ($9M), increasing execution and funding risk.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3272385

19 reports for ELAB

T+1T+5T+20T+60

40% Hit rate 2 of 5 directional calls best @ T+20▲ +42.86%Apr 20, 2026

Filters

Reports for ELAB — sortable, filterable
	Type				Now
Jun 8, 2026 6d ago	Press Release NEUTRAL ★ 4/10	$1.52 awaiting T+5	awaiting T+5	—	$1.47 (−3.29%)
Jun 5, 2026 9d ago	8-K NEUTRAL ★ 4/10	$1.55 awaiting T+5	awaiting T+5	—	$1.47 (−5.16%)
Jun 1, 2026 13d ago	Press Release NEUTRAL ★ 4/10	$1.77 $1.54	▼ −12.99%	▼ −10.24%	$1.47 (−16.95%)
May 13, 2026 4w ago	8-K MIXED ★ 7/10	$1.98 $1.75	▼ −11.62%	▼ −10.46%	$1.47 (−25.76%)
May 13, 2026 4w ago	Press Release NEUTRAL ★ 5/10	$1.98 $1.75	▼ −11.62%	▼ −10.46%	$1.47 (−25.76%)
Apr 23, 2026 7w ago	8-K MIXED ★ 6/10	$2.94 $2.53	▼ −13.95%	▼ −15.42%	$1.47 (−50.00%)
Apr 23, 2026 7w ago	Press Release NEUTRAL ★ 4/10	$2.94 $2.53	▼ −13.95%	▼ −15.42%	$1.47 (−50.00%)
Apr 21, 2026 7w ago	8-K BULLISH ★ 6/10	$3.29 $2.54	▼ −22.80%	▼ −23.88%	$1.47 (−55.32%)
Apr 20, 2026 7w ago	424B5 BEARISH ★ 6/10	$3.29 $2.54	▲ +22.80%	▲ +23.88%	$1.47 (+55.32%)
Apr 17, 2026 8w ago	8-K MIXED ★ 6/10	$3.28 $2.49	▼ −24.09%	▼ −24.64%	$1.47 (−55.18%)

US Market Status

Market Closed — Opens in 5h

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access